Background Treat-to-target (T2T) is a widely accepted management strategy for rheumatoid arthritis (RA) to achieve defined outcomes (remission or low disease activity). Moreover, mobile applications of patient-centered care created by multidisciplinary teams have been used for disease management in rheumatology. Smart System of Disease Management (SSDM) is a series of applications system for chronic diseases management.
Objectives To describe major clinical characteristics of Chinese RA patients using SSDM under T2T recommendation in real world.
Methods The SSDM includes doctors' application system and patients' application system. The patient application system includes self-assessment (DAS28, HAQ), medication management, adverse events management and laboratory records. After data entry, patients can synchronize data to the authorized doctor.
The data were collected online from 173 rheumatology centers that cover 27 provinces in China. All patients fulfilling the 1987 ACR (formerly the American Rheumatism Association) criteria for RA were recruited. The median of each variable was analyzed using t-test assuming normality for DAS28 distribution and the level disease activity was analyzed using Pearson's statistics.
Results Since December 14th, 2014 to January 25th, 2016, 2,585 patients, 1,854 (71.7%) women and 731 (28.3%) men, participated in this study. Average age was 49.4 ±12.86 (15–90) years with mean disease duration of 8.9 years. The mean DAS28 scores was 4.03±1.54 (0.62–8.84) and the mean HAQ scores was 2.80±4.33 (0–24). At the Baseline, 19.5% of patients got remission, 12.9% low disease activity (LDA), 43.5% moderate disease activity (MDA) and 24.1% high disease activity (HDA). Clinical remission rate was negatively correlated with HAQ scores. For the entire cohort, the most commonly used treatment were conventional DMARDs (92.7%) include leflunomide (65.52%), hdroxychloroquine (48.52%), methotrexate (39.00%) and sulfasalazine (5.77%).
Conclusions SSDM has provided demographic and clinical data of Chinese RA patients in real world practice. Clinical data and biologic samples would be valuable resources for future national and international studies.
Disclosure of Interest None declared